Inventors have found that CB1 inhibition (genetic invalidation or using a pharmacological peripheral blockade) reduces CKD and fibrosis in the severe renal ischemia reperfusion model, which represent an example of AKI to CKD transition, a common problem in patients. Therefore, CB1 inhibition represents an important therapeutic strategy in CKD, regardless of the cause. Inventors have performed preliminary experiments that demonstrate that CB1 inhibition represents an entirely novel target during ciliopathies. Accordingly, the present invention relates to a method for treating ciliopathies comprising a step of administering an inhibitor of Cannabinoid receptor 1 (CB1R) in a subject in need thereof.